Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
31 studies found for:    "Diffuse systemic sclerosis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Abatacept;   Drug: Placebo
2 Completed Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
Condition: Early Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Methotrexate;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide
3 Recruiting Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Conditions: Scleroderma, Diffuse;   Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: IVA337;   Drug: Placebo
4 Unknown  Serial Night Time Position Splint on Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Interventions: Device: Serial night time position splint;   Drug: Drug treatment
5 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
6 Active, not recruiting Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: JBT-101;   Drug: Placebo;   Drug: Part B Open-Label Extension
7 Recruiting Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: atorvastatin;   Drug: Placebo
8 Active, not recruiting Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan
9 Unknown  High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Condition: Scleroderma, Diffuse
Intervention: Drug: N-acetylcysteine (NAC)
10 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
11 Active, not recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Belimumab
12 Completed Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Condition: Systemic Sclerosis
Intervention: Drug: Relaxin
13 Recruiting Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: SAR156597 (ACT14604);   Drug: Placebo
14 Completed Mycophenolate Mofetil in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Intervention: Drug: Mycophenolate Mofetil
15 Unknown  AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Hyperimmune caprine serum;   Drug: Albumin
16 Recruiting IVIG Treatment in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Diffuse Scleroderma
Intervention: Biological: Privigen
17 Terminated Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: Imatinib mesylate;   Other: Placebo
18 Recruiting Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
Conditions: Scleroderma;   Cardiac Involvement;   Autologous Stem Cell Transplantation
Intervention: Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
19 Recruiting Autologous SCT for Progressive Systemic Sclerosis: a Prospective NIS Study
Condition: Autoimmune Diseases
Intervention: Procedure: Autologous HSCT
20 Withdrawn A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Condition: Scleroderma
Interventions: Drug: BMS-986020;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.